Orforglipron
ATTAIN-1
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 3127
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Population n/r | n/r | n/r | n/r | n/r |
| 6 mg Orforglipron | Population n/r | 6 mg | n/r | n/r | n/r |
| 12 mg Orforglipron | Population n/r | 12 mg | n/r | n/r | n/r |
| 36 mg Orforglipron | Population n/r | 36 mg | n/r | n/r | n/r |